TAK-981 is an inhibitor of SUMO-activating enzyme (SAE; IC50 = <10 nM). It increases macrophage phagocytosis and natural killer (NK) cell-mediated cytotoxicity of cancer cells in vitro. TAK-981 upregulates the expression of IFN-regulated genes in the blood and tumor tissue in an A20 syngeneic lymphoma mouse model. It also decreases intratumor levels of SUMOlyated proteins and reduces tumor growth in the same model.
TAK-981 is an inhibitor of SUMO-activating enzyme (SAE; IC50 = <10 nM). It increases macrophage phagocytosis and natural killer (NK) cell-mediated cytotoxicity of cancer cells in vitro. TAK-981 upregulates the expression of IFN-regulated genes in the blood and tumor tissue in an A20 syngeneic lymphoma mouse model. It also decreases intratumor levels of SUMOlyated proteins and reduces tumor growth in the same model.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.